drugset / Trial / NCT04918186
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Phase 2
Recruiting
60 enrolled
Canadian Cancer Trials Group
AstraZeneca · collabBioAtla, Inc. · collabCancer Research Institute, New York City · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
Timeline
- Start
- 2022-05-03
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | ENB003 | Unknown | — | — |
| Subject | Ozuriftamab Vedotin | Unknown | — | — |
| Subject | Toripalimab | Monoclonal antibody | — | — |
| Subject | mecbotamab vedotin | Unknown | — | — |